NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY
.
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2017-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Online Access: | https://www.rpcardio.online/jour/article/view/1386 |
| _version_ | 1797232201723543552 |
|---|---|
| author | article editorial |
| author_facet | article editorial |
| author_sort | article editorial |
| collection | DOAJ |
| description | . |
| first_indexed | 2024-03-08T14:02:43Z |
| format | Article |
| id | doaj.art-1847902e4bd94150a34c32ca6fc9f7af |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T15:56:31Z |
| publishDate | 2017-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-1847902e4bd94150a34c32ca6fc9f7af2024-04-01T07:43:34ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532017-01-011267667671297NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANYarticle editorial.https://www.rpcardio.online/jour/article/view/1386 |
| spellingShingle | article editorial NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY Рациональная фармакотерапия в кардиологии |
| title | NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY |
| title_full | NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY |
| title_fullStr | NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY |
| title_full_unstemmed | NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY |
| title_short | NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY |
| title_sort | new data of extensive research program and the results of studies in real clinical practice from different countries reaffirmed the high efficacy and a favorable safety profile of rivaroxaban xarelto r from the bayer company press release of the bayer company |
| url | https://www.rpcardio.online/jour/article/view/1386 |
| work_keys_str_mv | AT articleeditorial newdataofextensiveresearchprogramandtheresultsofstudiesinrealclinicalpracticefromdifferentcountriesreaffirmedthehighefficacyandafavorablesafetyprofileofrivaroxabanxareltofromthebayercompanypressreleaseofthebayercompany |